
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $7.46M |
| Gross Profit (TTM) | $-289.11M |
| EBITDA | $-406.59M |
| Operating Margin | 0.00% |
| Return on Equity | -44.80% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $0.35 |
| Book Value | $45.07 |
| Price-to-Book | 7.68 |
| Price-to-Sales (TTM) | 144.69 |
| EV/Revenue | 110.91 |
| EV/EBITDA | -6.86 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1349.00% |
| Shares Outstanding | $27.95M |
| Float | $24.10M |
| % Insiders | 0.28% |
| % Institutions | 128.23% |
Volatility is currently expanding

Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027

Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly - CFO & Treasurer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right. I think we're live now.

FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the fourth quarter of 2026 Cash and investments of approximately $1.3 billion as of September 30, 2026 maintain runway into 2028 Praxis to host an in-person and virtual Investor Day on November 12, 2026 and will participate in a fireside chat at the Guggenheim Biotech Summit today, November 9 at 9:30am ( register here ) BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter of 2026. “We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a commercial CNS company.

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on November 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 23,219 shares of its common stock to fifty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report financial results for the third quarter ended September 30, 2026, before the financial markets open on Monday, November 9, 2026. The Company also announced details of its upcoming Investor Day and participation in November investor conferences.

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on October 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,478 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

Praxis Precision Medicines NASDAQ: PRAX said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, or DEEs, as both new drug applications remain under FDA review.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRAX and any ticker you trade — then tracks every position and per-strategy win rate.